Tyra Biosciences, Inc.
Financials
Valuation Metrics
Tyra Biosciences, Inc.'s Market Cap is $1.53B. At end of 2025 it was $1.57B. Ranked #2239 of 3,121 in US market (top 72%), #891 of 1,463 on NASDAQ (top 61%), #166 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 62%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.53B | US#2,239/3,121 Sec#166/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-149M | US—/3,121 Sec—/266 |
| Total Assets | $383M | US#2,862/3,121 Sec#194/266 |
| Net Assets | $354M | US#2,450/3,121 Sec#147/266 |
| Employees | 87 | US#2,655/3,121 Sec#188/266 |
| Value | ||
| P/B | 4.33x | US#2,048/3,121 Sec#120/266 |
| FCF Yield | -7.18% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -42.01% | US#2,640/3,121 Sec#140/266 |
| ROA | -38.75% | US#2,943/3,121 Sec#188/266 |
| Financial Health | ||
| Debt Ratio | 8.40% | US#85/3,121 Sec#38/266 |
| Total Debt | $6M | US#2,896/3,121 Sec#214/266 |
| FCF | $-110M | US#2,648/3,121 Sec#150/266 |
| Cash | $74M | US#2,397/3,121 Sec#199/266 |
| Current Ratio | 14.91x | US#171/3,121 Sec#52/266 |
| Performance | ||
| 1Y Return | 101.17% | US#208/3,121 Sec#62/266 |
| 1M Return | -4.03% | US#1,927/3,121 Sec#151/266 |
| From 52W High | -36.70% | US#2,461/3,121 Sec#192/266 |
| 1Y MDD | -44.43% | US#2,229/3,121 Sec#162/266 |
| Trading | ||
| Volume | 1,802,025 shares | US#2,010/3,121 Sec#212/266 |
| Trading Value | $46M | US#2,208/3,121 Sec#180/266 |
| Per Share | ||
| EPS | $-2.50 | US—/3,121 Sec—/266 |
| BPS | $5.95 | US#2,199/3,121 Sec#112/266 |
Company Info
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.